98400-69-2

Basic information

• Product Name: 4-(Boc-amino)pyridine
• Synonyms: 4-(Boc-amino)pyridine tert-Butyl N-(4-Pyridyl)carbamate;Pyridin-4-yl-carbaMic acid tert-butyl ester;4-(BOC-AMINO)PYRIDINE;4-(TERT-BUTOXYCARBONYLAMINO)PYRIDINE;N-BOC-4-AMINO-PYRIDINE;TERT-BUTYL (PYRIDIN-4-YL)CARBAMATE;Carbamic acid, 4-pyridinyl-, 1,1-dimethylethyl ester (9CI);BOC-N-4-AMINO-PYRIDINE
• CAS NO: 98400-69-2
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.23
• Product Categories: Heterocycle-Pyridine series;amine;N-BOC;Heterocycles;Heterocyclic Compounds;CMLLYL
• Mol File: 98400-69-2.mol

Chemical Properties

• Melting Point: 145-149 °C
• Boiling Point: 252.743 °C at 760 mmHg
• Flash Point: 106.656 °C
• Appearance: /
• Density: 1.131 g/cm³
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12?+-.0.70(Predicted)
• CAS DataBase Reference: 4-(Boc-amino)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Boc-amino)pyridine(98400-69-2)
• EPA Substance Registry System: 4-(Boc-amino)pyridine(98400-69-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 98400-69-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-(Boc-amino)pyridine is used as a protected intermediate for the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. The Boc-protecting group allows for selective reactions to occur at the pyridine moiety without affecting the amino group.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-(Boc-amino)pyridine is used as a building block for the development of new drugs and drug candidates. Its versatility as a heterocyclic compound allows for the creation of diverse molecular structures with potential therapeutic applications.
Used in Research and Development:
4-(Boc-amino)pyridine is utilized in academic and industrial research settings for the investigation of new chemical reactions, synthesis methods, and the exploration of novel chemical entities with potential applications in various fields.
Overall, 4-(Boc-amino)pyridine is a valuable compound in the fields of chemistry and pharmaceuticals, serving as a protected intermediate and building block for the development of new molecules and therapeutic agents.

InChI:InChI=1/C10H14N2O2/c1-10(2,3)14-9(13)12-8-4-6-11-7-5-8/h4-7H,1-3H3,(H,11,12,13)

Upstream product

• 211029-67-3 (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 4427-22-9 4-pyridinecarbohydroxamic acid 
• 55-22-1 pyridine-4-carboxylic acid 
• 504-24-5 4-aminopyridine 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-65-0 tert-butyl alcohol 
• 89985-91-1 tert-butyl pyridin-2-yl carbonate 

Downstream Products

• 488720-30-5 3-(pyridin-4-yl)oxazolidin-2-one 
• 880545-30-2 C₁₇H₂₁N₂O₂⁽¹⁺⁾*Cl^(1-) 
• 171178-34-0 4-(tert-butoxycarbonylamino)pyridine-3-carboxylic acid 
• 365996-04-9 4-[(tert-Butoxycarbonyl)amino]-3-mercaptopyridine 
• 116026-93-8 4--3-pyridinecarboxaldehyde 
• 191338-96-2 ethyl 2-(4-((tert-butoxycarbonyl)amino)pyridin-3-yl)-2-oxoacetate 
• 37388-07-1 2-phenyl-1H-pyrrolo[3,2-c]pyridine 
• 271-34-1 5-azaindole 
• 191339-08-9 3-[(Z)-2-Amino-phenylimino]-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one 
• 169037-38-1 1H-pyrrolo[3,2-c]pyridine-2,3-dione 
• 227199-41-9 8-vinyl-[1,6]naphthyridine-2-carboxylic acid 2-isopropoxy-benzylamide 
• 197507-13-4 8-bromo-[1,6]naphthyridine-2-carboxylic acid (2-isopropoxybenzylamide) 
• 197507-11-2 [1,6]naphthyridine-2-carboxylic acid 2-isopropoxy-benzylamide 

Relevant articles and documents

Mechanized silica nanoparticles based on reversible bistable [2]pseudorotaxanes as supramolecular nanovalves for multistage pH-controlled release

Cucurbit[6]uril-based reversible bistable [2]pseudorotaxanes were designed, synthesized and installed on the surface of mesoporous silica nanoparticles as supramolecular nanovalves. The assembled mechanized silica nanoparticles realize the multistage pH-controlled release of benzotriazole and the potential for reutilization.

ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising aryl sulfonamide Stat3 small molecule inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use for treating cancer.

HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE

Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

A facile and versatile electro-reductive system for hydrodefunctionalization under ambient conditions

A general electrochemical system for reductive hydrodefunctionalization is described, employing the inexpensive and easily available triethylamine (Et3N) as a sacrificial reductant. This protocol is characterized by facile operation, sustainable conditions, and exceptionally wide substrate scope covering the cleavage of C-halogen, N-S, N-C, O-S, O-C, C-C and C-N bonds. Notably, the selectivity and capability of reduction can be conveniently switched by simple incorporation or removal of an alcohol as a co-solvent.

18F-LABELLED COMPOUND FOR PROSTATE CANCER DIAGNOSIS, AND USE THEREOF

The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron

A Greener Approach for the Chemoselective Boc Protection of Amines Using Sulfonated Reduced Graphene Oxide as a Catalyst in Metal- And Solvent-Free Conditions

Sulfonated reduced graphene oxide (SrGO) has displayed great potential as a solid acid catalyst due to its efficiency, cost-effectiveness, and reliability. In this study, SrGO was synthesized by the introduction of sulfonic acid-containing aryl radicals onto chemically reduced graphene oxide using ultrasonication. The SrGO catalyst was characterized by Fourier Transform Infrared (FTIR) spectroscopy, Raman spectroscopy, powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS) and transmission electron microscopy (TEM). Further, SrGO was effectively utilized as a metal-free and reusable solid acid catalyst for the chemoselective N - t -Boc protection of various aromatic and aliphatic amines under solvent-free conditions. The N - t -Boc protection of amines was easily achieved under ambient conditions affording high yields (84-95percent) in very short reaction times (5 min-2 h). The authenticity of the approach was confirmed by a crystal structure. The catalyst could be easily recovered and was reused up to seven consecutive catalytic cycles without any substantial loss in its activity.

Larotinib derivative and preparation method and application thereof

The invention relates to a larotinib derivative and a preparation method and application thereof, and provides a novel larotinib derivative with anti-tumor activity. The novel larotinib derivative isbeneficial to improving the anti-tumor activity of the l

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors

Indoleamine 2,3-dioxygenase 1 (IDO1) is regarded as a promising target for cancer immunotherapy. Many naphthoquinone derivatives have been reported as IDO1 inhibitors so far. Herein, two series of naphthoquinone derivatives, naphthoindolizine and indolizinoquinoline-5,12-dione derivatives, were synthesized and evaluated for their IDO1 inhibitory activity. Most of the target compounds showed significant inhibition potency and high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO). The structure-activity relationship was also summarized. The most potent compounds 5c (IC50 23 nM, IDO1 enzyme), and 5b′ (IC50 372 nM, HeLa cell) were identified as promising lead compounds.

Design, synthesis, and evaluation of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives as Aurora kinase inhibitors

A series of hinge-binder tethered 1,2,3-triazolylsalicylamide derivatives were designed, synthesized, and evaluated for the Aurora kinase inhibitory activities. The novel hinge-binder tethered 1,2,3-triazolylsalicylamide scaffold was effectively assembled by Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC). A variety of alkynes with hinge binders were used to search proper structures-binding relationship to the hinge region. The synthesized 1,2,3-triazolylsalicylamide derivatives showed significant Aurora kinase inhibitory activity. In particular, 8a inhibited Aurora A kinase with an IC50 value of 0.284 μM, whereas 8m inhibited Aurora B kinase with an IC50 value of 0.364 μM.